Strategic Partnerships Leverage StimLabs existing and expanding distribution agreements with Geistlich (Derma-Gide) and Geistlich particulate collagen, as well as Vizient national contract coverage, to target hospitals and wound care networks seeking bundled regenerative biologics and advanced wound care solutions.

New Product Rollout Capitalize on Architect Fx and Corplex P launches to position StimLabs as a source for innovative extracellular matrix products for wound management, targeting wound care centers, surgical departments, and regenerative medicine programs seeking high-end biomaterials.

Private Equity & Leadership Monitor leadership movements such as the SVP of Finance transition to Germfree, signaling potential strategic or financing shifts; explore investment discussions or partnership opportunities with growth-minded stakeholders and private equity networks aligned with regenerative medicine.

Regional Expansion Pursue expansion in Georgia and broader U.S. markets leveraging existing US commercialization activities with Geistlich and new Vizient contracts to accelerate adoption among inpatient and outpatient wound care and surgery teams.

Health System Access Use StimLabs’ integrated tech stack and cloud infrastructure to offer scalable supply, training, and data-enabled outcomes tracking to health systems; emphasize the value proposition of comprehensive regenerative biologics portfolios for full-thickness wounds, with physician-endorsed products.